Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite strong Zola sales growth and distribution expansion, the company faces significant challenges such as missing EPS expectations, declining cash reserves, and increased SG&A expenses. The lack of forward guidance and unclear management responses in the Q&A further add to investor uncertainty. The pending transaction with Roosevelt Resources and the decline in GLA oil sales also pose risks. These factors are likely to result in a negative stock price movement.
Key Financial Performance
Total Revenues Q4 2024 $1.2 million, an increase of 56% year-over-year, driven by a 124% increase in Zola revenues despite a decline in GLA oil sales.
Total Revenues Full Year 2024 Just over $5 million, a 13% increase compared to 2023, primarily driven by a 46% increase in Zola sales, offsetting a 49% decline in GLA oil sales.
Gross Profit Q4 2024 $0.384 million, with a gross margin of 32%, reflecting a decline from 51% in 2023 due to a shift in product sales mix.
Gross Profit Full Year 2024 $2.1 million, with gross margins of 41.3%, down from 51% in 2023, driven by increased costs associated with Zola sales.
R&D Expenses 2024 $53,000, a decrease of $11,000 compared to 2023, reflecting a strategy to leverage existing resources for Zola brand development.
SG&A Expenses 2024 $9.6 million, an increase from $8.2 million in 2023, including $2 million of transaction costs related to the sale of GoodWheat assets.
SG&A Expenses Q4 2024 $2.7 million, including $700,000 of transaction-related costs, compared to $1.7 million in Q4 2023.
Cash at Year End 2024 $4.2 million, down from $11.6 million at the start of the year, reflecting reduced operating cash consumption in the second half.
Accounts Receivable at Year End 2024 $1.2 million, up from $500,000 at the start of the year, reflecting growth in Q4 Zola revenues.
Inventory at Year End 2024 $904,000, up from $837,000 at the start of the year, due to higher Zola revenues and longer lead times from suppliers.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Zola Revenue Growth: Zola sales increased 46% compared to the previous year, with a 124% increase in Q4 alone.
Distribution Expansion: Zola grew retail distribution by 86%, adding over 1,600 new stores in 2024.
Cost Management: Operating cash consumption decreased by 30% in the second half of 2024 compared to the first half.
Gross Margin: Zola gross margins in 2024 were 33%, consistent with previous guidance.
Business Restructuring: Exited underperforming Body Care brands to focus on Zola and monetized wheat IP through the sale of GoodWheat.
Pending Transaction: Entered into a definitive securities exchange agreement with Roosevelt Resources, expected to complete by end of Q2 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Expectations: Arcadia Biosciences reported an EPS of $-2.99, missing expectations of $-0.89, indicating potential financial instability.
Transaction-Related Costs: SG&A costs included $2 million of transaction costs related to the sale of GoodWheat assets and pending transaction with Roosevelt Resources, which may affect future profitability.
Cash Consumption: Despite reducing operating cash consumption by 30% in the second half of 2024, the company ended the year with $4.2 million in cash, down from $11.6 million at the start of the year, indicating liquidity risks.
Inventory Management: The increase in inventory to $904,000 reflects longer lead times from coconut water suppliers, which could pose supply chain challenges.
Regulatory Issues: The pending transaction with Roosevelt Resources is subject to SEC review, which could delay the completion and impact operational plans.
Sales Decline in GLA Oil: A 60% decline in GLA oil sales in the second half of 2024 raises concerns about product diversification and reliance on Zola for revenue.
Market Competition: Zola's growth is outpacing the coconut water category, but competitive pressures remain as consumer preferences shift towards healthier beverages.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Focus on Zola Brand: Arcadia has exited underperforming Body Care brands to concentrate resources on Zola coconut water products.
Monetization of Wheat IP: In mid-2024, Arcadia monetized a portion of its wheat intellectual property portfolio, providing non-dilutive capital and reducing operating expenses.
Distribution Gains: Zola achieved significant distribution gains, adding over 1,600 new stores and growing retail distribution by 86%.
Cost Management: The company has successfully reduced operating cash consumption by 30% in the second half of 2024.
Pending Transaction with Roosevelt Resources: Arcadia is in the process of a transaction with Roosevelt Resources, expected to complete towards the end of Q2 2025.
2024 Revenue Guidance: Full year revenue expected to be in line with $5.3 million reported for 2023.
Gross Profit and Margins: Gross profit expected to be above $2 million with gross margins in the low 40s.
R&D and SG&A Expenses: R&D and SG&A expenses projected to have a quarterly run rate of around $2 million in the second half of 2024.
Zola Sales Growth: Zola sales increased 46% in 2024, with gross margins consistent with guidance in the low to mid-30s.
Future Growth Outlook: Zola is expected to maintain momentum with new distribution and opportunities for additional growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Pending Transaction with Roosevelt Resources: Arcadia Biosciences has entered into a definitive securities exchange agreement with Roosevelt Resources, which is expected to involve share issuance and a stockholder vote on related proposals.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate a bit on your expectations for continued distribution growth here in 2025?
A:We do have a healthy pipeline as we enter 2025. I don’t want to provide any specific numbers. But the pipeline is as healthy in ’25 as it was in ’24.
Q:What was the full year GLA revenue and then also in the fourth quarter? And can you confirm you guys are 100% sold out of that product as of 12/31/24?
A:Full year GLA revenue was $756,000. Q4 was $55,000. We are completely out of GLA inventory, there will be no GLA sales in 2025.
Q:Can you update us on the status of any efforts to monetize the legacy IP from the prior business model?
A:We still have a portfolio of patents predominantly focused on wheat. We are seeking to monetize that entire patent portfolio, likely through a series of transactions. We are in advanced stages of discussions and hopeful to have something done in the first half of the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers regarding distribution growth expectations for 2025, which lacked clarity. Additionally, while they mentioned being in advanced stages of discussions for monetizing the legacy IP, they did not provide specific details on the timeline or potential buyers.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arcadia Biosciences
Arcadia path
Arcadia revenue
Arcadia sale
Arcadia sport
Biosciences Full
Commission security
Conference Instructions
Dallas Texas
Exchange Commission
Form SEC
Inc expectation
RD SGA
Roosevelt Resources
SGA rate
Transcript Arcadia
agreement Roosevelt
comment
expectation afternoon
fact
number product
opportunity
profitability
proposal transaction
registration statement
review process
sale GoodWheat
shelf
stockholder
story
success
transaction Roosevelt
wheat
RKDA Transcript
Earnings call transcript: Arcadia Biosciences sees Q1 2025 revenue rise 22%
Unknown5-8
The earnings call presents a mixed picture. While the Zola brand shows strong sales growth and distribution expansion, gross margins are declining, and the company is transitioning to a single product line. Although the cash position is healthy, regulatory issues and unclear management responses in the Q&A create uncertainty. The revenue guidance is stable but not growing, and the completion of a key transaction is delayed. These factors suggest a neutral stock price movement in the near term.
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2024 Earnings Call Transcript
Unknown3-22
Despite strong Zola sales growth and distribution expansion, the company faces significant challenges such as missing EPS expectations, declining cash reserves, and increased SG&A expenses. The lack of forward guidance and unclear management responses in the Q&A further add to investor uncertainty. The pending transaction with Roosevelt Resources and the decline in GLA oil sales also pose risks. These factors are likely to result in a negative stock price movement.
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript
Neutral3-20
Arcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call Transcript
Neutral3-20
RKDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
